Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease

The main advantages of using ALA for ECP are (1) highly effective and selective apoptotic destruction of transformed/activated hyper-proliferative T-cells through an endogenously selective production of the potent photosensitiser, protoporphyrin IX (PpIX) from ALA via heme biosynthetic pathway; (2) ALA/PpIX only targets membranous structures outside of the cell nucleus thus causing no risk of carcinogenesis and (3) induces systemic anti-tumour immunity.

Inclusion criteria

• Informed consent
• cutaneous T-cell lymphoma (CTCL) (Mycosis fungoides and Sézary syndrome)
• considered to respond inadequately to 8-MOP-ECP therapy. Inadequate response is defined as:

• progressive disease: disease progression from baseline in skin score, blood or lymph nodes after 3-6 months or
• stable disease: No- response after 3-6 months or
• minimal response < 50% (from baseline) reduction of skin scores and/or CD4/CD8 ratio or a loss of peripheral blood clone after 3-6 months.
• (or) chronic graft-versus-host disease (cGvHD) and considered to respond inadequately to 8-MOP-ECP therapy. Chronic GvHD is defined as

• presence of at least 1 clinical sign of cGvHD or
• at least one distinct manifestation confirmed by pertinent biopsy or other relevant tests.
• steroid dependence, intolerance or steroid refractoriness considered to respond inadequately to 8-MOP-ECP therapy with at least monthly intervals.

Inadequate response is defined as:

• progression of cutaneous cGvHD defined as >25% worsening from baseline as measured by the percent change in the total skin score or
• after 3 months had an inadequate response of cutaneous cGvHD as defined by <15% improvement in the total skin score compared with baseline, or a ≤25% reduction in corticosteroid dose.

Exclusion criteria

• Photosensitive comorbidities, porphyria or known hypersensitivity to 5-aminolevulinic acid or porphyrins
• Aphakia
• Pregnancy or breast feeding. (A negative urine pregnancy test must be demonstrated in female patients of child-bearing potential at the Screening Visit)
• Ongoing cardiac and pulmonary diseases or ASAT, ALAT, Bilirubin or INR value ≥ 3x upper limit of normal or clinically significant ECG findings
• Polyneuropathy
• Uncontrolled infection or fever
• History of heparin-induced thrombocytopenia, absolute neutrophil count <1x10-9 L-, platelet count <20x10-9 L-1
• Body weight below 40 kg
• Investigator considers subject unlikely to comply with study procedures, restrictions and requirements.
• History of any clinically significant disease or disorder which in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result or the patient's ability to participate in the study.